昭衍新药公告,公司决定注销因终止2021年及2022年A股员工持股计划涉及的回购股份,合计注销12.911万股。其中,回购专用账户中注销3.312万股,2022年员工持股计划账户中注销9.59万股。本次注销不会对公司财务状况和经营成果产生实质性影响。董事会已取得股东大会授权办理相关事项。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.